<p>The investigational antibody-drug conjugate (ADC) micvotabart pelidotin (MICVO, PYX-201) demonstrated promising antitumor activity and a manageable safety profile in a Phase I trial presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics by researchers at The Universit</p>